<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472885</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-101</org_study_id>
    <secondary_id>2016-003526-16</secondary_id>
    <secondary_id>U1111-1209-4655</secondary_id>
    <nct_id>NCT03472885</nct_id>
  </id_info>
  <brief_title>A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab</brief_title>
  <acronym>PNH</acronym>
  <official_title>A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness of ACH-0144471 in improving anemia when given with eculizumab
      for 24 weeks in patients with PNH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effectiveness of ACH-0144471 in improving
      anemia, as measured by increased blood hemoglobin, when given with eculizumab (a drug
      commonly used for treatment of PNH) for 24 weeks in patients with PNH.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Four groups will be studied and enrolled sequentially.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Hemoglobin (Hgb) During the 24-Week Treatment Phase Compared to Baseline: Optimal Dose Group</measure>
    <time_frame>Baseline (Day 1), up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Hemoglobin (Hgb) During the 24-Week Treatment Phase Compared to Baseline: Non-Optimal Dose Groups</measure>
    <time_frame>Baseline (Day 1), up to 24 weeks</time_frame>
    <description>Median Hgb over the time period that the participant received the highest dose level during the 24-week treatment phase compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Units of Red Blood Cells (RBCs) Transfused During 24 Weeks of Treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Without RBC Transfusions During 24 Weeks of Treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Without RBC Transfusions During 24 Weeks of Treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lactate Dehydrogenase (LDH) During 24 Weeks of Treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Grade 3 and Grade 4 Adverse Events (AEs), and Events Leading to Discontinuation of Study Drug</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>Group 1: 100 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ACH-0144471 TID to start in combination with eculizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 150 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg ACH-0144471 TID to start in combination with eculizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 200 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg ACH-0144471 TID to start in combination with eculizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Optimal Dose of ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal dose (100 mg, 150 mg or 200 mg, as determined from Groups 1-3) of ACH-0144471 TID to start, in combination with eculizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471</intervention_name>
    <description>All patients will receive a daily oral dose of ACH-0144471 TID during the treatment period.</description>
    <arm_group_label>Group 1: 100 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 2: 150 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 3: 200 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 4: Optimal Dose of ACH-0144471 TID + Eculizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>All patients will receive intravenous (IV) eculizumab administered at the patient's usual dose and schedule.</description>
    <arm_group_label>Group 1: 100 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 2: 150 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 3: 200 mg ACH-0144471 TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 4: Optimal Dose of ACH-0144471 TID + Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosed with PNH

          -  18 to 65 years of age

          -  Have received at least one RBC transfusion within last 12 weeks

          -  Anemia with adequate reticulocytosis

          -  Must be on a stable regimen of eculizumab

          -  Platelet count ≥ 40,000/μL without the need for platelet transfusions

          -  Documentation of vaccination for N. meningitidis, H. influenza, and S. pneumoniae or
             willingness to receive vaccinations based on local guidelines

          -  Willingness to receive antibiotic prophylaxis

          -  Female participants must use highly effective birth control to prevent pregnancy
             during the clinical trial and for 30 days after their last dose of study drug.

          -  Male participants must use a highly effective birth control with a female partner to
             prevent pregnancy during the clinical trial and for 90 days after the last dose of
             study drug.

        Key Exclusion Criteria:

          -  Current evidence of bone marrow failure or aplastic anemia requiring treatment

          -  History of a major organ transplant or hematopoietic stem cell/marrow transplant

          -  Received another investigational agent within 30 days or 5 half-lives of the
             investigational agent prior to study entry, whichever is greater

          -  Documented C5 mutations

          -  Known or suspected complement deficiency

          -  Contraindication to any of the required vaccinations

          -  Active bacterial infection or clinically significant active viral infection, a body
             temperature &gt;38°C, or other evidence of infection

          -  History of meningococcal infection, or a first-degree relative or household contact
             with a history of meningococcal infection

          -  History of hypersensitivity reactions to commonly used antibacterial agents

        NOTE: Additional inclusion/exclusion criteria may apply, per protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>+1 203-752-5577</phone>
    <email>PNHTrialInquiries@achillion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Dorr</last_name>
      <phone>410-502-2547</phone>
      <email>dorrdo@jhmu.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Brodsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Kaufman</last_name>
      <phone>216-445-1019</phone>
      <email>kaufmas3@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Jaroslaw Maciejewski, M.D., Ph.D.</last_name>
      <phone>+1-216-445-5962</phone>
      <email>maciejj@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jaroslaw Maciejewski, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNH</keyword>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>eculizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

